Spero Therapeutics (SPRO) Revenue (QoQ) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.51% |
| Dec 31, 2025 | -235.04% |
| Sep 30, 2025 | -61.65% |
| Jun 30, 2025 | 141.56% |
| Mar 31, 2025 | -80.59% |
| Dec 31, 2024 | 46,447.69% |
| Sep 30, 2024 | -98.90% |
| Jun 30, 2024 | -36.30% |
| Mar 31, 2024 | -85.86% |
| Dec 31, 2023 | 29,965.60% |
| Sep 30, 2023 | -91.97% |
| Jun 30, 2023 | 1,117.94% |
| Mar 31, 2023 | -98.67% |
| Dec 31, 2022 | 736.24% |
| Sep 30, 2022 | 0.65% |
| Jun 30, 2022 | -3.67% |
| Mar 31, 2022 | -86.60% |
| Dec 31, 2021 | 2,081.07% |
| Sep 30, 2021 | -66.38% |
| Jun 30, 2021 | -71.15% |
| Sep 30, 2020 | -97.80% |
| Jun 30, 2020 | 1.53% |
| Mar 31, 2020 | 144.40% |
| Dec 31, 2019 | -85.01% |
| Sep 30, 2019 | 6,829.85% |
| Jun 30, 2019 | -99.13% |
| Mar 31, 2019 | 356.15% |
| Dec 31, 2018 | 157.14% |
| Sep 30, 2018 | 42.12% |
| Dec 31, 2017 | 66.33% |
| Sep 30, 2017 | 139.76% |
| Jun 30, 2017 | 77.86% |
| Mar 31, 2017 | 315.38% |
| Dec 31, 2016 | -165.00% |